Gemcitabine is used for: Lung cancer; pancreatic cancer; bladder cancer; breast cancer; ovarian carcinoma.
Recorded in the NepalDoc medicine catalog for Gemcitabine.
Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy., in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.…
From the U.S. FDA-approved label for Gemcitabine. Full label: DailyMed.
Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy., in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated., in combination with cisplatin for the treatment of non-small cell lung cancer., as a single agent for the treatment of pancreatic cancer. 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
From the U.S. FDA-approved label for Gemcitabine. Full label: DailyMed.
Gemcitabine Injection is for intravenous use only., Ovarian Cancer: 1000 mg/m 2 over 30 minutes on Days 1 and 8 of each 21-day cycle., Breast Cancer: 1250 mg/m 2 over 30 minutes on Days 1 and 8 of each 21-day cycle., Non-Small Cell Lung Cancer: 1000 mg/m 2 over 30 minutes on Days 1, 8, and 15 of each 28-day cycle or 1250 mg/m 2 over 30 minutes on Days 1 and 8 of each 21-day cycle., Pancreatic Cancer: 1000 mg/m 2 over 30 minutes once weekly for the first 7 weeks, then one-week rest, then once weekly for 3 weeks of each 28-day cycle.
Directions from the U.S. FDA-approved label for Gemcitabine — your doctor or pharmacist may advise differently.
Gemcitabine Injection is contraindicated in patients with a known hypersensitivity to gemcitabine. Reactions include anaphylaxis. Patients with a known hypersensitivity to gemcitabine.
Excerpt from the U.S. FDA-approved label for Gemcitabine. Talk to a pharmacist or doctor before use.
Schedule-Dependent Toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly., Myelosuppression: Monitor for myelosuppression prior to each cycle and reduce or withhold dose for severe myelosuppression., Severe Cutaneous Adverse Reactions (SCARs): Permanently discontinue Gemcitabine Injection if SCARs occur., Pulmonary Toxicity and Respiratory Failure: Discontinue Gemcitabine Injection for unexplained dyspnea or other evidence of severe pulmonary toxicity., Hemolytic Uremic Syndrome (HUS): Monitor renal function prior to initiation and during treatment.
Warnings and precautions excerpt from the U.S. FDA-approved label for Gemcitabine — not a complete list. Talk to a pharmacist or doctor before use.
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity, Schedule-Dependent Toxicity, Myelosuppression, Severe Cutaneous Adverse Reactions, Pulmonary Toxicity and Respiratory Failure, Hemolytic Uremic Syndrome, Hepatic Toxicity, Exacerbation of Radiation Therapy Toxicity, Capillary Leak Syndrome, Posterior Reversible Encephalopathy Syndrome The most common adverse…
Excerpt from the U.S. FDA-approved label for Gemcitabine — not a complete list. Talk to a pharmacist or doctor about side effects.
10 brands · 5 makers in the NepalDoc catalog — see the full Gemcitabine guide →
Store at 2° to 8°C (36° to 46°F).
Storage information from the U.S. FDA-approved label for Gemcitabine.
What is Gemwel?
Gemwel 200mg Injection is a Gemcitabine medicine made by Getwell Pharmaceuticals. It comes as 200mg Injection.
What is Gemwel used for?
Gemcitabine is used for Lung cancer, pancreatic cancer, bladder cancer, breast cancer, ovarian carcinoma.
What is the generic name of Gemwel?
The generic name of Gemwel is Gemcitabine.
Which brands of Gemcitabine are available in Nepal?
10 brands of Gemcitabine are listed in the NepalDoc catalog, from 5 makers — including C-Celza 1gm Injection, C-Celzar 200mg Injection, Cytogem 1g Injection, Cytogem 200mg Injection, Gemcite 1gm Injection, Gemcite 200mg Injection.
What are the side effects of Gemcitabine?
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity, Schedule-Dependent Toxicity, Myelosuppression, Severe Cutaneous Adverse Reactions, Pulmonary Toxicity and Respiratory Failure, Hemolytic Uremic Syndrome, Hepatic Toxicity, Exacerbation of Radiation Therapy Toxicity, Capillary Leak Syndrome, Posterior Reversible Encephalopathy Syndrome The most common adverse…
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
